In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Lundbeck licenses Merz's Alzheimer's disease compound

Executive Summary

Psychiatric and neurological pharmaceutical company Lundbeck AS licensed exclusive development and marketing rights in Europe to Merz's (also CNS therapeutics) memantine, which has completed four Phase III trials for treating Alzheimer's disease and vascular dementia.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • R+D and Marketing-Licensing

Related Companies

UsernamePublicRestriction

Register